Alaunos Therapeutics (NASDAQ: TCRT) is a clinical-stage biopharmaceutical company developing an oral, small-molecule drug candidate for obesity and metabolic disorders. The company generates no product revenue and funds operations through equity issuances, including common stock, pre-funded warrants, and Series A preferred stock offerings. As of March 31, 2026, Alaunos had one full-time employee. The company previously operated a TCR-T cell therapy program under an exclusive worldwide license from MD Anderson Cancer Center, which it wound down in August 2023 following a strategic reprioritization. Its sole active program is ALN1003, a non-hormonal, non-incretin oral small-molecule candidate targeting obesity. The company competes against significantly larger pharmaceutical and biotechnology companies with greater financial resources, clinical development experience, and commercial infrastructure. Efforts to sell or out-license its legacy intellectual property portfolio have been unsuccessful as of the filing date.

Revenue model

No product revenue. Operations are funded through equity financings, including issuances of common stock, pre-funded warrants, Series A-1 preferred stock, and Series A-2 preferred stock. The company has no approved products and no commercial-stage assets as of the 10-K filed March 31, 2026.

Products and services

ALN1003: an oral, small-molecule obesity candidate with a non-hormonal, non-incretin mechanism of action, currently in preclinical development. Animal studies in diet-induced obese (DIO) mice showed dose-related reductions in body weight, liver weight, white adipose tissue, blood glucose, and total cholesterol. Legacy assets include intellectual property from former TCR-T cell therapy programs, including rights originally licensed from MD Anderson Cancer Center in January 2015; efforts to monetize this portfolio have been unsuccessful as of the filing date.

Customers and end markets

No commercial customers. Target end market is obesity and metabolic disorders. The company has no approved products and has not advanced ALN1003 to human clinical trials as of the 10-K filed March 31, 2026.

Value-chain role

Early-stage drug discovery and preclinical development. The company does not manufacture, market, or distribute any commercial product. Historical research was conducted under license and R&D agreements with MD Anderson Cancer Center and the National Cancer Institute; active clinical development under those arrangements ended in August 2023.

Geographic exposure

Incorporated and operating in the United States. Regulatory development pathway referenced is the U.S. FDA process under the Federal Food, Drug, and Cosmetic Act.

Competitors

Novo Nordisk, Eli Lilly, Amgen, Pfizer, Viking Therapeutics, Structure Therapeutics

Source: SEC 10-K, filed 2026-03-31

Industry: Pharmaceutical Preparations Peers: 2seventy bio, Inc. ADMA Biologics Inc Allakos Inc. Aura Biosciences Inc Entrada Therapeutics Inc Imago BioSciences, Inc. Precigen Inc Rallybio Corp